Angiotensin receptor blockers in hypertension. New insights from Japan

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Angiotensin II receptor blockers (ARBs) are established treatments for hypertension, heart failure, and diabetic nephropathy.
• Previous studies indicate ARBs reduce cardiovascular events in hypertensive patients, similar to ACE inhibitors.
• Emerging evidence suggests ARBs may provide cardiovascular protection independent of their blood pressure-lowering effects.

Purpose of the Study:

• To investigate the cardiovascular protective effects of valsartan, an ARB, in a pooled analysis of two Japanese trials (JIKEI and Kyoto studies).
• To determine if the benefits of ARBs on major cardiovascular events are independent of achieved blood pressure reduction.

Main Methods:

• A pooled analysis of data from the JIKEI and Kyoto studies was conducted.
• Both studies utilized a prospective randomized open blinded end point (PROBE) design.
• Valsartan treatment efficacy was compared against a control group, with a focus on achieved blood pressure levels.

Main Results:

• Valsartan significantly reduced the primary composite outcome by 42% (P<0.0001).
• Significant reductions were observed for angina pectoris (38%; P<0.0001), heart failure hospitalization (43%; P=0.013), and cerebrovascular events (42%; P=0.002).
• No significant differences in achieved blood pressure were noted between the valsartan and control groups.

Conclusions:

• Valsartan demonstrates significant protective effects against major cardiovascular events, including heart failure and stroke.
• These benefits appear to be partly independent of the degree of blood pressure reduction achieved.
• The findings support the concept that angiotensin II inhibition offers cardiovascular protection beyond mere antihypertensive action.